HIV Seropositivity
65
2
5
41
Key Insights
Highlights
Success Rate
89% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
7.7%
5 terminated out of 65 trials
89.1%
+2.5% vs benchmark
11%
7 trials in Phase 3/4
17%
7 of 41 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 41 completed trials
Clinical Trials (65)
A Multilevel, Multiphase Optimization Strategy for PrEP (MOST:PrEP)
Immuno-virological Evaluation of Persons Living With HIV (PLWH)
Assessing the PrEP Care Cascade Among Black Men and Transwomen in the Southeastern US
Implementation of STTR Strategies Among People Who Inject Drugs in Malaysia
Clinical Trial of Gammora® Plus Antiretroviral Treatment for HIV
Telehealth Delivery (Tele-B6)
Hybrid Type I Effectiveness-Implementation Trial of a Social Network Support Intervention
Screen, Treat and Retain Meth-using People With Opioid Use Disorders at Methadone Clinics
Safety and Tolerability of 1 Month Daily (1HP) and 3 Months Weekly (3HP) Isoniazid and Rifapentine With Pharmacokinetics of Dolutegravir (DTG) in Pregnant People With HIV
Comparing Treatment Completion Of Daily Rifapentine & Isoniazid For One Month (1HP) To Weekly High Dose Rifapentine & Isoniazid For 3 Months (3HP) In Persons Living With HIV and in Household Contacts of Recently Diagnosed Tuberculosis Patients
A Pilot Study of Metformin to Reduce Cerebrovascular Dysfunction in Participants With HIV and Metabolic Syndrome.
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
iTransition Development
Simplification Study of HIV-1 Infected Patients With Virological Suppression Under the Combination of Lamivudine (150 mg BID) Plus Raltegravir (400 mg BID) Switching to Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) : Roll-over Study of the RALAM
Study With Dual Therapy Including Lamivudine (300 mg QD) Plus Raltegravir (1200 mg QD) in Virologically Suppressed HIV-1 Infected Patients Experiencing Inconvenience, Toxicity, Negative Impact on Co-morbidities or Risk of Drug-drug Interactions With Their Current Regimen
Collision of Three Global Pandemics: the Effect of Tuberculosis and HIV on the Epidemiological, Clinical, Virological and Immunological Trajectory of COVID-19 in Botswana and Namibia
Evaluation of Post-SARS-CoV-2 Vaccinal Response in Immunocompromised Patients
Precariousness and Sexual Vulnerability of People From Haiti Living With or Without HIV in French Guiana
Lower Urinary Tract Symptoms in Males Living With HIV
National Survey About Trajectory and Life Conditions of HIV Trans People in France